Traders who prefer options can buy puts or sell calls on the approval price spike, betting the share price will pull back before the options expire. More experienced traders can also build complex options setups, such as butterflies or condors, to take advantage of the implied volatility in share price and creating windows of maximum profitability before the actual FDA decision is announced.

Traders who don't mind taking a bit more risk can even short Alexza just before the expected FDA decision. If FDA surprises the market by rejecting Adasuve, Alexza's stock price will plummet and the trading profits will be huge. An advantage to shorting pre-approval is that finding shares to short post approval can be difficult.

Messier has no current position in Alexza but he may short the stock following the FDA decision on Friday.
Mark Messier is the founder of BioRunUp.com. Messier is a DOJ-certified Criminal Intelligence Analyst and former IT professional, specializing in law enforcement applications. In 2008, Messier began trading biotech stocks, using his analytical expertise to detect and capitalize on human and market patterns. Starting with only $2,200 in his trading account, he has booked over $400,000 in profit in just 4 years. In April 2010, Messier founded the subscription-based stock-trading web site BioRunUp.com to share his biotech trading ideas with the online investor community. Messier enjoys spending time with his wife and two young boys and visiting his "home away from home" in Costa Rica.

If you liked this article you might like

3 Stocks Pushing The Drugs Industry Lower

Market News: Apple Inc, Vitae Pharmaceuticals, Alexza Pharmaceuticals

Why to Buy These 5 Under-$10 Stocks ASAP

5 Stocks Under $10 Set to Soar

7 Under-$10 Stocks Racing Higher